文献速递造血干细胞移植与细胞治疗

诱导性调节性T细胞预防HLA相合同胞移植后GVHD的首次人体1期试验

First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings.
PubMed 文献 · Blood Adv · 2021-01-01

该1期单中心剂量递增研究评估了诱导性调节性T细胞(iTregs)在高危恶性肿瘤患者接受HLA相合同胞供者清髓性减低预处理及动员外周血干细胞移植后的安全性。14例可评估患者中,联合环孢素(CSA)和霉酚酸酯(MMF)时iTregs最高剂量3.0×10^8/kg未出现严重输注毒性,10例该剂量患者中7例无急性GVHD;而西罗莫司/MMF方案因2例均发生3级急性GVHD而中止。

要点

  • iTregs联合CSA/MMF可安全输注至3.0×10^8/kg,无严重输注毒性。
  • 该剂量下10例中7例无急性GVHD,2例2级,1例3级。
  • 西罗莫司/MMF方案因2例均发生3级急性GVHD而暂停。

核心结论

  • iTregs在CSA/MMF背景下可安全输注至3.0×10^8/kg,并观察到急性GVHD发生率较低。

研究设计与样本

  • 1期单中心剂量递增研究,纳入16例高危恶性肿瘤成人患者,14例接受iTregs治疗,供者为HLA相合同胞。

主要发现

  • 14例接受iTregs联合CSA/MMF治疗的患者均无严重输注毒性,中性粒细胞恢复中位第13天。
  • 10例接受3.0×10^8/kg iTregs联合CSA/MMF的患者中,7例无急性GVHD,2例2级,1例3级。
  • 接受西罗莫司/MMF的2例患者均发生3级急性GVHD,导致该方案暂停。
  • 循环Foxp3+ iTregs可检测至第14天。

关键数值与推荐

  • iTregs剂量递增至3.0×10^8/kg,对应T传统细胞与iTreg比例分别为86:1、8:1和1:2。

临床怎么用

  • iTregs联合CSA/MMF可作为HLA相合同胞移植后GVHD预防的潜在策略,需进一步验证疗效。

局限性

  • 1期单中心小样本研究,主要评估安全性,疗效需更大规模试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human CD4+25- T cells cultured in interleukin 2 (IL-2), rapamycin, and transforming growth factor β (TGFβ) along with anti-CD3 monoclonal antibody-loaded artificial antigen-presenting cells generate FoxP3+ induced regulatory T cells (iTregs) with potent suppressive function. We performed a phase 1, single-center, dose-escalation study to determine the safety profile of iTregs in adults with high-risk malignancy treated with reduced-intensity conditioning and mobilized peripheral blood stem cells (PBSCs) from HLA-identical sibling donors. Sixteen patients were enrolled and 14 were treated (2 productions failed to meet desired doses). One patient each received 3.0 × 106/kg, 3.0 × 107/kg, and 3.0 × 108/kg iTregs with corresponding T-conventional-to-iTreg ratios of 86:1, 8:1, and 1:2. After 3 patients received 3.0 × 108/kg in the presence of cyclosporine (CSA) and mycophenolate mofetil (MMF) with no dose-limiting toxicities, subsequent patients were to receive iTregs in the presence of sirolimus/MMF that favors Foxp3 stability based on preclinical modeling. However, 2 of 2 developed grade 3 acute graft-versus-host disease (GVHD), resulting in suspension of the sirolimus/MMF. An additional 7 patients received 3.0 × 108/kg iTregs with CSA/MMF. In the 14 patients treated with iTregs and CSA/MMF, there were no severe infusional toxicities with all achieving neutrophil recovery (median, day 13). Of 10 patients who received 3.0 × 108/kg iTregs and CSA/MMF, 7 had no aGVHD, 2 had grade 2, and 1 had grade 3. Circulating Foxp3+ iTregs were detectable through day 14. In summary, iTregs in the context of CSA/MMF can be delivered safely at doses as high as 3 × 108/kg. This trial was registered at www.clinicaltrials.gov as #NCT01634217.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. MacMillan ML, Hippen KL, McKenna DH, et al. First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. Blood Adv. 2021. PMID: 33666654. doi:10.1182/bloodadvances.2020003219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。